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Background: Photodynamic therapy with aminolevulinic acid (ALA PDT) for oral leukoplakia has shown
promising effects in regression of oral leukoplakia. Although ALA has been extensively studied and is
an ideal photosensitizer, the optimal light dose for treatment of oral leukoplakia has not been deter-
mined. We conducted a phase I study to determine MTD and DLT of PDT in patients treated with ALA
for leukoplakia.
Methods: Patients with histologically conﬁrmed oral leukoplakia received a single treatment of ALA PDT
in cohorts with escalating doses of light (585 nm). Clinical, histologic, and biologic markers were
assessed.
Results: Analysis of 11 participants is reported. No signiﬁcant toxicity from ALA PDT was observed in
patients who received ALA with a light dose of up to 4 J/cm2. One participant experienced transient grade
3 transaminase elevation due to ALA. One participant had a partial clinical response 3 months after treat-
ment. Biologic mucosal risk markers showed no signiﬁcant associations. Determination of MTD could not
be accomplished within a feasible timeframe for completion of the study.
Conclusions: ALA PDT could be safely administered with a light dose up to 4 J/cm2 and demonstrated
activity. Larger studies are needed to fully elucidate the MTD and efﬁcacy of ALA-PDT.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Introduction
Each year in the United States over 40,000 new cases of head
and neck squamous cell cancer (HNSCC) are diagnosed, with
approximately 27,000 of these cases occurring in the oral cavity
or pharynx [1]. Oral cavity cancer is associated with a poor
prognosis with 5 year survival rates of less than 50% [1]. While
incremental advances have been achieved in the management
of SCCHN, our failure to achieve substantial improvements inprognosis for the majority of SCCHN patients underscores the need
to investigate effective strategies for cancer prevention.
The presentation of potentially malignant disorders of the oral
cavity is highly variable. Cytologic dysplasia, which occurs when
architectural disturbance is accompanied by cytologic atypia,
correlates well with subsequent development of invasive squa-
mous cell carcinoma [2]. Leukoplakia is a condition characterized
by a white patch or plaque involving the oral mucosa. Leukoplakia
may coexist with varying grades of dysplasia and is generally also
considered to be a potentially malignant disorder. Oral leukoplakia
is therefore an excellent clinical model for examining the cancer
prevention strategies.
Photodynamic therapy (PDT) involves the topical or systemic
administration of a photosensitizing agent that, in the presence
of light corresponding to an optimal wavelength, creates reactive
oxygen species capable of inducing cytotoxic damage. Aminolevu-
linic acid (ALA) is a photosensitizing agent that is an endogenous
metabolite present in virtually all mammalian cells. It is the
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metabolic precursor of the endogenously formed photosensitizer,
protoporphyrin IX (PpIX). Upon exposure to light within one of
the absorption peaks of PpIX (410–635 nm), cytotoxic free radical
species are generated. Based upon its biochemical properties, ALA
has a number of potential advantages compared to other photosen-
sitizing agents. ALA is excreted rapidly, which limits its potential
phototoxic side effects. Administration of ALA bypasses the nega-
tive feedback control of its metabolic pathway, and leads to selec-
tive accumulation of PpIX in mucosal and epithelial tissues [3]. By
preferentially accumulating in the mucosa, rather than the under-
lying stroma, PpIX thereby reduces damage to deeper layers. In
addition, several reports suggest that PpIX may accumulate prefer-
entially in dysplasia and tumor rather than normal tissue [4,5].
Use of PDT for Barrett’s esophagus is well established. A consid-
erable number of published reports have examined the use of ALA
as a photosensitizer for PDT in Barrett’s mucosa [6–10]. Signiﬁ-
cantly less information exists regarding ALA PDT for oral leukopla-
kia. However, available data on ALA PDT for oral leukoplakia is
promising [11–13]. Small single institution studies have examined
various doses of both topical and orally administered ALA, followed
by light therapy of varying light intensities from 100 to 200 J/cm2.
These studies have had in common observations of high response
rates, deﬁned by complete and partial resolution of macroscopic
disease, but also frequent observations of acute pain of sufﬁcient
degree to require analgesia. Unfortunately, these trials did not rig-
orously examine toxicity in relation to the optimal dose or sche-
dule of light intensity. In the present trial we examined ALA PDT
in oral leukoplakia to determine the optimal light intensity when
given with a ﬁxed dose of orally administered ALA, as well as tox-
icity and tolerability and association with mucosal risk markers.Participants and methods
Participants
Subjects eligible for the study were required to have histologi-
cally conﬁrmed oral leukoplakia with dysplasia OR with hyperpla-
sia in a high-risk area (ﬂoor of mouth, tongue or oropharynx).
Subjects with oral leukoplakia with hyperplasia in a NON-high-risk
location (such as frictional keratoses in the buccal mucosa from
ill-ﬁtting dentures) were not eligible. Patients with previous early
stage (I and II) head and neck cancer were eligible if disease free for
2 years following deﬁnitive treatment. Prior treatment, including
experimental therapy was permissible if experimental treatment
was completed >3 months prior to study entry. Other eligibility
criteria were as follows: age > 18 years; Zubrod < 1; adequate or-
gan function deﬁned by: Hgb > 12 gm/dl, platelets > 100,000/lL,
ANC > 1500/lL, creatinine 6 1.5 mg/dl, SGPT and SGOT 6 1.5
the institutional upper limit of normal (ULN), total bilirubin 6 1.5
the institutional ULN; life expectancy > 2 years; signed written
informed consent.Treatment and dose escalation schedule
ALA was provided by DUSA Pharmaceuticals Inc. (Wilmington,
MA) with long pulse dye laser 585 nm (nm) using Cynosure Photo-
Genica SV pulsed dye laser system. ALA powder was administered
by mouth as a single dose dissolved in 50 ml of water 3–4 h before
light treatment. The initial dose of ALA was 60 mg, but this was
amended to 30 mg after a participant experienced grade 3 trans-
aminase elevation ascribed to ALA. Participants were given strict
instructions for light protection for 24 h following ALA administra-
tion. A laser spot size of 10 mm was used with a speciﬁc laser set-
ting (Joules) to achieve the desired ﬂuence (Joules/cm2).Dose escalation cohorts were planned with 4 participants per
cohort – each corresponding to a light dose from 2 to 8 J/cm2 by
increments of 2 J/cm2. The ﬁrst cohort received no ALA. Subsequent
cohorts received a ﬁxed dose of ALA without escalation. Light dose
escalation was performed according to the following plan: if dose
limiting toxicity (DLT), deﬁned as any grade 3 toxicity, was experi-
enced in at least 1 of 4 participant in a cohort, 2 more participants
were to be treated on the next lower dose cohort (N = 6). If an addi-
tional participant on the lower dose cohort experienced one or
more DLTs, additional participants were to be enrolled on the next
lower cohort until either a dose cohort had 0/6 participants with
DLTs or the lowest dose cohort had treated 6 participants. If 0/4
participants experienced DLT(s) at the highest dose cohort, 2 addi-
tional participants were to be enrolled at that cohort. The maxi-
mum tolerated dose, MTD, was deﬁned as the highest dose at
which 0 of 6 experienced grade 3 or greater toxicity.
All four subjects in a dose level had to complete 1 month of fol-
low-up without dose limiting toxicity (DLT) prior to enrollment of
subjects in the next dose level. Only one subject was to be treated
at a time; the next subject on the same dose level was not to be
treated until the prior subject had completed safety assessment
at 24–48 h following treatment. Safety assessment was performed
at 24–48 h, 14 days, and 1 and 3 months post-PDT. Toxicities were
graded according to the NCI Common Terminology Criteria for Ad-
verse Events (CTCAE) version 3. As participants only received ALA
and PDT one time, no dose modiﬁcation was planned for any given
participant. DLT was deﬁned as being any grade 3 toxicity, with the
exception of asymptomatic LFTs < 15 the upper limit of normal
(ULN) that resolved to grade 2 or lower by day 14. Dose escalation
was planned to continue in the presence of grade 2 toxicity. If a
DLT was experienced in at least 1 of 4 participants in a given co-
hort, 2 more individuals were to be treated on the next lower dose
cohort (N = 6). If an additional participant on the lower dose cohort
experienced one or more DLTs, additional subjects were to be en-
rolled on the next lower cohort until either a dose cohort had 0/6
subjects with DLTs or the lowest dose cohort had treated 6 pa-
tients. If 0/4 subjects were to experience DLT(s) at the highest dose
cohort, 2 additional patients were to be enrolled in that cohort. The
maximum tolerated dose (MTD) was deﬁned as the highest dose at
which 0 of 6 participants experienced grade 3 or greater toxicity.
Deﬁnitions of response
Clinical response was deﬁned as follows: Complete response—
disappearance of all measurable disease; Partial response—
decrease in the cross-sectional areas of a measurable leukoplakia
lesion by at least 50% in the product of the two longest diameters
of a single lesion in the absence of new ‘‘in ﬁeld’’ lesions; Stable
disease—decrease in the cross-sectional area of a measurable
leukoplakia lesion by <50% of the product (or sum of products) of
measured lesion(s) diameters in the absence of new ‘‘in ﬁeld’’ le-
sions; Progressive disease—increase in the product (or sum of
products) of the measured lesion diameters by P25% or develop-
ment of a new ‘‘in ﬁeld’’ leukoplakia lesion. If multiple lesions were
treated, then the sum of all lesions was used. ‘‘Out of ﬁeld’’
progression was documented but not used in response analysis.
Response was deﬁned based upon the status of disease at the
3 month time point.
Histologic evaluation of all biopsies was performed indepen-
dently by two pathologists who were blinded to clinical data.
Biopsy samples were scored according to the extent of dysplasia
on a 5-point ordinal scale (no dysplasia, mild, moderate, or severe
dysplasia, and carcinoma in situ) as previously described [14].
Graders used a scoring system for hyperplasia based upon estab-
lished ranges of normal mucosal thickness from the literature at
speciﬁc anatomic sites. Hyperplasia was graded as mild, moderate,
972 S.J. Wong et al. / Oral Oncology 49 (2013) 970–976or extensive. Histologic response was determined by comparison
of pre- and post-treatment biopsies for both severity of dysplasia
and extent of hyperplasia.
Mucosal risk markers
Punch biopsies of target lesions were performed at baseline (be-
tween 8 and 4 weeks before start of therapy) and at completion
3 months following therapy. Markers of proliferation (Ki-67),
apoptosis (TUNEL, p53), and signal transduction modulation (cy-
clin D1) were performed by immunohistochemistry (IHC) on paraf-
ﬁn-embedded tissue. Mucosal risk was also assessed by DNA
ploidy analysis.
Immunohistochemistry
The expression of p53, cyclin D1, Ki-67 and TUNEL were as-
sessed in oral biopsy samples. Immunohistochemistry was per-
formed using the Leica Bond Max and Polymer automated
detection systems (Leica Microsystems, Wetzlar, Germany). The
following antibodies were used for marker detection: For p53,
mouse antihuman monoclonal Ab (DO-7), (PA0057; Leica Biosys-
tems, United Kingdom), ready to use (RTU) antibody optimized
for Bond Leica detection system; For cyclin D1, rabbit monoclonal
Ab (EP 12)(AP-0017; Epitomics, Burlingame, CA), RTU antibody
optimized for Bond Leica detection system; For Ki67 (MM1), RTU
Bond antibody (PA0057; Leica Biosystems, United Kingdom) opti-
mized for Bond Leica detection system; For TUNEL, Apoptosis
Detection Kit (S7101; Millipore, Billerica, MA) was used. Finally,
sections were slightly counterstained with hematoxylin for 7 min
and blued in 0.4% ammonia water followed by rehydration and
cover slip mounting.
All of the above markers were validated according to protocol
standardization at Pathology Core Facility, Robert H. Lurie Compre-
hensive Cancer Center, Northwestern University, Chicago, IL.
Appropriate known control tissue was used for positive control
and primary Abs were omitted in negative controls.
Immunohistochemistry evaluation
TUNEL staining was evaluated by counting positively-stained
pyknotic bodies. All the cells of the squamous epithelium in each
biopsy excluding cells of the Stratum corneum (corniﬁed layer
with ﬂattened, fused cell remnants) were taken into evaluation.
The staining score was performed based on the following
classiﬁcation:
0, No staining.
1, Weak staining.
2, Moderate staining; and
3, Strong stains.
The IHC biomarker score was assessed by counting positively
stained nuclei with respect to all the squamous epithelial nuclei
which include Stratum basale, S. spinosum and S. granulosal layers.
Staining with a score of 2 and 3 are considered as positive. IHC
score index is then converted to a percentage ﬁgure.
For the automated determination of Ki67, cyclin D1 and p53,
stained slides were scanned using a TissueFAXS (TissueGnostics,
Vienna, Austria) Image Acquisition and Management Software.
Visualization and automated cell counts were carried out using
the HistoQuest system version 3.0.3 (TissueGnostics, Vienna,
Austria). Digitized slides were evaluated using the program’s nu-
clear scoring algorithm, which quantiﬁes nuclear staining within
biopsy specimens and derives a counting score for each target area
[15]. Nuclei stained with polymerized di-aminobenzidine and/or
hematoxylin were identiﬁed and separated by a thresholding and
segmentation algorithm. Using the HistoQuest the investigatorwas able to adjust the upper and lower limits of a range of accept-
able nuclear areas, such that cells within the speciﬁed range were
accepted for analysis, whereas those out of the range were re-
jected. Thus sub-epithelial stromal elements and inﬂammatory
cells were excluded from the analysis through sampling and auto-
mated gating restrictions respectively. Only the lower 5 cell layers
from basement membrane were considered for the automated
evaluation. The ﬁnal counts were represented as percentage of nu-
clei stained positive to total nuclei in the selected region. Several
regions from each biopsy were averaged to get the ﬁnal result. Cut-
off parameters for nuclear staining were deﬁned based on the neg-
ative control and background immunohistochemical staining.
Nuclear staining was classiﬁed as positive or negative based on ob-
server-speciﬁed intensity thresholds.
DNA ploidy was performed as previously described [14,16,15].
Cytophotometric parameters were derived from formalin-ﬁxed
parafﬁn-embedded tissue, sectioned at 8 lm thick and stainedwith
blue Feulgen DNA ploidy analysis staining kit (DPK500-IFU, ScyTek
Laboratories, UT). Internal non-lesional control cells were selected
manually as ACIS control reference to compare the sample cells of
interest. The ACIS generated a histogram from the collected cells
based on the raw integrated optical density (IOD) values of digital
nuclear images. An internal control peak was assigned to internal
non-lesional cells (>30 per biopsy) containing normal amount of
DNA with which all biopsy cells (not lesion speciﬁc) were com-
pared. Control nuclei were used to set the DNA Index (DI) to 1.0.
(DI = DNA unknown/DNA diploid control). This peak marked the
position of diploid population. Tonsil tissue was used as an external
run control for staining and IOD determination. The mean
integrated optical density (IOD) of control cells was assigned a
DNA Index (DI) of 1, which served as an internal diploid (2N) stan-
dard and reference for DI calculation of the targeted cells. DI of 1.1
was assigned as an upper limit of the normal euploid range.Results
Between April 2008 and March 2010, 11 participants were en-
rolled and received protocol therapy. Table 1 summarizes the par-
ticipant characteristics, demographics, and treatment doses levels.
Dysplasia severity represents the worst pre-treatment histology.
Table 2 summarizes adverse events and grade of toxicity for all
related events for all participants. No severe (grade 3 or 4) toxicity
was observed except for one participant (Pt #5), who experienced
transient grade 3 transaminase elevation that resolved to baseline.
Because this toxicity was a known side effect of ALA, the protocol
was amended with ALA dose reduction from 60 mg to 30 mg for
subsequent participants. No further events of liver dysfunction
were observed in subsequent participants. The study was discon-
tinued prior to completion due to slow accrual. DLT was not ob-
served in the participants who completed treatment and MTD
was not identiﬁed. No mucosal toxicity was observed. Participants
reported neither acute nor delayed pain, sensitivity, swelling, or
burning associated with photodynamic therapy.
No clinical responses (complete or partial) were observed in the
treated participants; neither was there any clinical progression of
lesions. However, participant #10, who had two leukoplakia le-
sions in the treatment ﬁeld of the oral tongue, was observed to
have a 50% decrease in one lesion and signiﬁcant reduction in
the mucosal prominence of the other lesion; by size criteria this
did not reach the deﬁnition of partial response (see Fig. 1). Follow-
ing the completion of protocol follow-up assessments, this partic-
ipant was observed clinically, off-protocol, and eventually achieved
complete resolution of the treated leukoplakia lesions by
6 months. As of the last clinical assessment, 1.25 years post com-
pletion of therapy, complete clinical resolution persists in the
Table 1
Participant pretreatment characteristics and treatment dose levels.
Pt# Age Sex Lesion location ALA dose (mg/kg) Fluence (J/cm2)
1 71 M Oral tongue 0 4
2 70 M Oral cavity (alveolar ridge) 0 4
3 67 F Oral cavity (lip) 0 4
4 64 M Oral tongue 0 4
5 49 M Oral tongue 60 2
6 50 M Oral tongue 30 2
7 74 F Oral tongue 30 2
8 65 F Oral tongue 30 2
9 66 F Oral tongue 30 2
10 68 F Oral tongue 30 4
11 48 M Oral tongue 30 4
Table 2
Adverse events and grade for possible, probable and deﬁnitely related events.
ALA dose (mg) Light dose (J/cm2) Adverse event Grade
60 2 ALT elevation 3
60 2 AST elevation 3
60 2 Urine color change 1
60 2 Skin photosensitivity 2
30 2 Nausea 1
30 2 Pruritus 1
30 2 Palpitations 1
30 4 Nausea 1
30 4 Skin Photosensitivity 1
30 4 Vomiting 1
S.J. Wong et al. / Oral Oncology 49 (2013) 970–976 973treatment port although an out of ﬁeld new leukoplakia lesion has
been detected in the contralateral oral tongue.
Histologic response is shown in Table 3. Reduction in hyperpla-
sia score, frommoderate to mild, was observed in two participants,
while increase in hyperplasia score was observed in one subject
who increased from moderate to severe. Reduction in dysplasia
was observed in 3 participants who received no ALA, and one par-
ticipant who received 60 mg of ALA and 2 J/cm2. Reduction dyspla-
sia from severe to none was observed in one participant (#2—no
ALA) who subsequently went on to experience out of ﬁeld oral can-
cer progression. Subject #10, who achieved late complete clinical
response, had no dysplasia at baseline but mild dysplasia at
3 months.
Three study participants experienced cancer progression
subsequent to completion of protocol therapy. Participant #2
(cohort 1—no ALA) developed an out of ﬁeld oral squamous cellFigure 1 Participant #10: Clinical and histologic appearance of leukoplakia lcancer 4 months after protocol PDT therapy. Participant #5 (cohort
2–60 mg/kg ALA, 2 J/cm2) also developed an out of ﬁeld oral squa-
mous cell cancer 2 years after completion of protocol therapy.
Participant #4 (cohort 1—no ALA) was diagnosed with squamous
cell cancer from an area of the oral tongue consistent with the trea-
ted leukoplakia lesion 3.3 years following completion of protocol
therapy. Two of these participants had either moderate or severe
baseline dysplasia.
Mucosal risk markers were performed on biopsies from all trea-
ted participants. Apoptosis as evaluated by TUNEL staining and
quantiﬁcation revealed negligible values at baseline and at
3 months (data not shown). Expression of p53, cyclin D1, and cell
proliferation (Ki-67) are shown in Figs. 2–4, respectively. DNA ploi-
dy analysis is shown in Table 4. No signiﬁcant associations were
seen in the comparisons between baseline and post-treatment val-
ues of the biologic mucosal risk markers. Baseline aneuploidy
spanned a wide range from 35% to 87%. The participants who expe-
rienced off study oral cancer progression had baseline levels on the
high end of this spectrum but did not have unusually high percent-
age of polyploid cells. Participant 10, who achieved complete
clinical resolution of leukoplakia, showed no unusual histologic
or mucosal marker changes.
Discussion
Incremental improvements have been made in the manage-
ment of oral cavity HNSCC such as in post-operative combined
modality treatment [17]. However, transformational break-
throughs that have signiﬁcantly improved the prognosis for oralesions at various time points: (D) Baseline, (E) 3 months, (E2) 6 months.
Table 3
Histologic assessment: hyperplasia and dysplasia severity at baseline and 3 months.
Pt. # Hyperplasia baseline Hyperplasia 3 months Dysplasia baseline Dysplasia 3 months
1 Moderate Moderate None None
2 Moderate Mild Severe None
3 Mild Mild Mild None
4 Mild Mild Mild None
5 Moderate Extensive Moderate None
6 Moderate Moderate Mild Mild
7 Moderate Moderate Mild Mild
8 Moderate Moderate Mild Mild
9 Mild Mild None Mild
10 Mild Mild None Mild
11 Moderate Mild Mild None
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Figure 2 Percentage of p53 expression for each participant at baseline and 3 months.
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Figure 3 Percentage of cyclin D1 expression for each participant at baseline and 3 months.
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underscores the continued need to study new cancer prevention
approaches for oral pre-malignant conditions. With this goal in
mind, we conducted a clinical trial to examine an ALA PDT for
treating oral leukoplakia. Despite our inability to complete planned
accrual, we have shown that, with light dose levels up to 4 J/cm2,
no signiﬁcant toxicity was encountered. One of two participants
treated at this dose level achieved a persistent clinical response
in the treated lesions, suggesting potential clinical efﬁcacy that
should be investigated further.
We observed no adverse toxicity related to mucosal damage, in
contrast to other ALA PDT studies that examined 628–635 nm light
at much higher light intensity (100–200 J/cm2) and observed sig-
niﬁcant pain in 30–44% of participants [12,13]. Our observationof tolerability of low light intensity is in agreement with the phase
I/II study by Shaﬁrstein et al. that examined 585 nm laser doses
from 6 to 8 J/cm2 with topical or intralesional injected ALA. In this
study only minor pain effects were observed at the 6 and 7 J/cm2
dose levels [18]. The MTD was 8 J/cm2—dose limiting pain, requir-
ing analgesia, was observed at this level. This study also demon-
strated therapeutic efﬁcacy with 7/17 patients (41%) achieving
signiﬁcant response—deﬁned as at least 75% resolution of the
lesion. Other oral cavity ALA PDT clinical studies examined higher
light intensity (>100 J/cm2) but did not rigorously examine report
toxicity and tolerability [22–26]. It is also not clear whether higher
light intensity is associated with increased efﬁcacy, however it
does appear that increased mucosal damage and pain may be clo-
sely correlated. Similarly, no conclusions can be drawn from this
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Table 4
DNA Ploidy. DI = Diploidy Index, difference in DNA content expressed as the ratio of DNA ﬂuorescence of leukoplakia sample/normal tissue sample.
Patient ID Time of biopsy % of diploid cells Avg. DI of diploid cells (range) % of aneuploid cells % of polyploid cells Avg. DI of polyploid cells (range)
1 Baseline 65 0.84(0.23–1.1) 35.4 0.8 2.23 (2.0–2.48)
3 mos. 27 0.86(0.73–1.1) 73 1 2.31 (2.0–2.43)
2 Baseline 30 0.89(0.73–1.1) 70 0.1 2.57 (2.0–2.73)
3 mos. 39 0.93(0.78–1.1) 61 5.3 2.2 (2.0–2.96)
3 Baseline 14.2 0.98(0.85–1.1) 86 15.2 2.33 (2.0–4.52)
3 mos. 25.85 0.94(0.76–1.1) 73.95 0 2.03 (2.02–2.05)
4 Baseline 33 0.94(0.74–1.1) 67 1 2.46 (2.0–2.77)
3 mos. 49 0.99(0.85–1.1) 51 0.3 2.48 (2.0–3.02)
5 Baseline 41.7 0.96(0.77–1.1) 58.3 2.2 2.11 (2.0–2.36)
3 mos. n/a n/a n/a n/a n/a
6 Baseline 48.7 0.94(0.75–1.1) 51.3 n/a 2.31 (2.0–3.91)
3 mos. 12.78 0.92(0.73–1.1) 87.2 37 2.35 (2.0–4.33)
7 Baseline n/a n/a n/a n/a
3 mos. 39.5 0.93(0.72–1.1) 60.4 4.2 2.57 (2.02–3.47)
8 Baseline 30 0.93(0.75–1.1) 70 2.1 2.41 (2.0–2.86)
3 mos. 44.8 0.94(0.72–1.1) 55.1 2.2 2.52 (2.03–3.48)
9 Baseline 23 0.89(0.79–1.1) 76.8 2.4 2.36 (2.0–2.8)
3 mos. 28.1 0.91 (0.75–1.1) 71.9 2.5 2.21 (2.0–2.38)
10 Baseline 43.8 0.92(0.75–1.1) 56.2 0 2.42 (2.0–3.24)
3 mos. 40 0.95(0.78–1.1) 59 1.6 2.34 (2.0–2.8)
11 Baseline 62 1 (0.63–1.1) 38 1.3 2.29 (2.0–2.35)
3 mos. 53 0.97 (0.82–1.1) 47 1.2 2.31 (2.0–3.6)
S.J. Wong et al. / Oral Oncology 49 (2013) 970–976 975limited data set regarding optimal light wavelength, so long as it is
at one of the absorption peaks for protoporphyrin IX. In the context
of this disease in which re-treatment may be required due to its
propensity for recurrence and multifocal behavior, the importance
of future studies to determine treatment parameters that optimize
the therapeutic ratio of ALA PDT cannot be overstated.
Several limitations were encountered in the conduct of our
study that reﬂect common issues encountered in chemoprevention
clinical trials. The design of the light dose cohorts was planned to
carefully delineate toxicity—in particular, purpura which can be
caused by laser light damage rather than PDT effects from ALA.
However, these rigorous design requirements also increase the
sample size and duration of the study. Compared to therapeutic
trials, chemoprevention clinical trials can pose unique challenges
that can dramatically affect accrual [19]. For instance, accrual of
participants with a pre-exisiting potentially malignant disorders,
such as leukoplakia, to a chemoprevention study may rely upon
casting a much wider geographic net. This, in turn, can be compli-
cated by the fact that expanded population pools may also have
alternative choices for experimental therapy. Two national studies
overlapped with our study—Pioglitazone for Oral PremalignantLesion Study (NCT009513790), and the Erlotinib Prevention of Oral
Cancer Study (NCT00402779).
While we observed no signiﬁcant toxicity related to the light
alone or ALA PDT, we did observe one participant who experienced
transient grade 3 transaminase elevation. Infrequent occurrences
of transient transaminase elevation from ALA have been well
described in the literature [8]. A study amendment to modify
the dose of ALA was instituted following this event. Based upon
the data from Barrett’s esophagus studies that routinely use
60 mg/kg, it could be argued that use of the standard ALA dose of
60 mg/kg is reasonable for use in future ALA PDT studies for oral
leukoplakia as well. In contrast to chemoprevention studies with
long term interventions where moderate to severe toxicities can-
not be tolerated over long periods of time, such toxicities (as long
as they are brief and rapidly reversible) may be acceptable in the
setting of single, time-limited intervention such as ALA-PDT. Given
that, some efﬁcacy was seen in one participant treated with 30 mg
ALA and a light dose of 4 J/cm2, this lower dose of ALA should be
investigated ﬁrst.
The absence of treatment-related pain is likely attributable to
the relatively low light intensity that was used. In contrast, other
976 S.J. Wong et al. / Oral Oncology 49 (2013) 970–976reported studies used much higher light intensity with commensu-
rate higher incidence of pain.
Of note, three of the treated study participants later developed
squamous cell carcinoma of the oral cavity, well after the comple-
tion protocol therapy. In two cases the tumors occurred outside of
the laser treatment port. Given the estimate that 30% of patients
with oral leukoplakia later develop SCCHN within an 8 year period,
this observation is not unusual [20]. However, these data do raise a
potential shortcoming of ALA PDT. While ALA PDT could be effec-
tive in ablating potentially malignant lesions, this therapy is not
likely to reduce this incidence of subsequent cancers due to ﬁeld
cancerization effect. Lee and colleagues have shown in patients
with leukoplakia, 59% of subsequent cancers occurred at the site
of the previous leukoplakia, while 41% occurred elsewhere [20].
Thus systemic therapy, alone or as a complement to PDT, may be
a more desirable approach. Systemic therapy is not without chal-
lenges as it would likely need to be administered for a lengthy per-
iod of time and thus its effectiveness is likely to be more inﬂuenced
by toxicity and compliance issues. Perhaps a local treatment ap-
proach to potentially malignant lesions, such as PDT, coupled with
oral screening, offers another potential approach to cancer risk
reduction in this high risk population. The results of our trial show
that future clinical studies that seek to deﬁnitively examine the
efﬁcacy of ALA PDT must take into consideration out of ﬁeld cancer
progression as a study endpoint and that long term follow-up is
important for all leukoplakia studies.
Observed of changes in histologic grade of dysplasia or hyper-
plasia were inconclusive in this study. This may be primarily due
to insufﬁcient sampling. However, it is important to note that his-
tologic endpoints have certain inherent uncertainties that compli-
cate their utility in assessing response [21]. Variability of histology
within a single leukoplakia lesion or between different lesions in
the same patient may be highly divergent. Thus a baseline biopsy
may not accurately reﬂect the overall severity of disease. Likewise,
a post therapy biopsy may not accurately reﬂect true overall re-
sponse to an intervention. Two of the participants with the worst
baseline dysplasia score did subsequently go on to have oral cancer
progression. We observed no clear association between baseline
and post therapy measurements of mucosal risk markers. How-
ever, analogous to histologic grading, mucosal risk markers have
inherent uncertainties that limit interpretation.
In summary, this study did not reach its primary endpoint
regarding the optimal dosing or toxicity of ALA PDT for oral leuko-
plakia. We observed no signiﬁcant toxicity and one participant
treated at the 4 J/cm2 dose level achieved a delayed but durable
complete clinical response. Our experience points out the necessity
for future studies, potential beneﬁt of this approach, and highlights
potential pitfalls that should be considered in the design of future
phase I studies of photodynamic therapy for leukoplakia.
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